![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BMS to Acquire Padlock Therapeutics for $600M
BMS to Acquire Padlock Therapeutics for $600M
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/Bristol_Meyers_Squibb_logo.jpg?t=1444401319&width=430)
Bristol-Myers Squibb has agreed to acquire Padlock Therapeutics in a deal worth up to $600 million.
The deal includes upfront and near-term milestone payments of up to $225 million and an additional $375 million upon completion of regulatory milestones.
Cambridge, Mass.-based Padlock focuses on autoimmune diseases. With the acquisition, BMS gains access to Padlock’s protein/peptidyl arginine deiminase inhibitor discovery program.
The parties expect the deal to close in the second quarter.
Upcoming Events
-
21Oct